NTRK2 Genotype

Two people can have identical cholesterol, glucose, and thyroid labs and still carry very different inherited risks for anxiety, mood disorders, severe obesity, or how their body responds to certain antidepressants. Some of that hidden difference traces back to a single gene called NTRK2 (neurotrophic receptor tyrosine kinase 2), which builds a docking station on cells that receives a brain growth signal called BDNF (brain-derived neurotrophic factor).

This test reads your inherited NTRK2 sequence to flag variants linked to anxiety liability, antidepressant response, rare neurodevelopmental syndromes, and rare forms of single-gene obesity. It is one of the few ways to see whether a gene that shapes both brain plasticity and appetite control is working with you or against you.

What NTRK2 Actually Does

NTRK2 carries the instructions for building TRKB, a receptor that sits on the surface of neurons and a few other cell types. When BDNF (the main signal that helps brain cells grow, connect, and survive) lands on TRKB, the receptor turns on chains of internal signals that control neuron survival, the strength of connections between brain cells, and appetite regulation in the hypothalamus (the brain's appetite control center).

Because TRKB sits at the receiving end of this signal, inherited differences in NTRK2 can quietly tune how strongly your brain responds to BDNF. Most variants have small effects. A small number have large effects and cause distinct syndromes, with two opposite directions: variants that ramp up TRKB signaling are linked to severe developmental delay, epilepsy, and visual problems, while variants that knock TRKB function down are linked to milder developmental delay plus obesity and intense hunger.

Mood, Anxiety, and Brain Wiring

A genome-wide study of lifetime anxiety disorders, drawing on more than 83,000 participants, identified a stretch of DNA overlapping NTRK2 that meets the strictest statistical bar for involvement in anxiety. In other words, common variation in this gene contributes to how likely you are to develop an anxiety disorder over your lifetime, not just acute stress reactions.

In a separate study of more than 2,000 healthy young adults, a common NTRK2 variant was linked to emotional arousal and to differences in the structural integrity of white matter, the long-distance wiring that connects brain regions. A single study of essential tremor found that carriers of the C allele at NTRK2 rs1187280 were less likely to have tremor (odds ratio 0.626), a finding that should be interpreted cautiously until replicated. An African-ancestry bipolar disorder study flagged NTRK2 rs2769605 as a suggestive risk variant.

Antidepressant and Mood Stabilizer Response

If you have ever wondered why one person responds well to an SSRI while another sees no benefit at all, NTRK2 has been studied as one of many possible contributors. Several studies have reported associations between specific NTRK2 variants and how people respond to antidepressants and mood stabilizers, though the evidence is mixed and at least one well-powered study found no association.

Sources: Dong et al. 2009, Hennings et al. 2013, Deflesselle et al. 2017, Camarena et al. 2025. What this means for you: NTRK2 is not currently part of standard pharmacogenomic panels (such as CPIC guidelines), and the evidence for using it to guide antidepressant choice is preliminary and inconsistent. If depression treatment has been frustrating, NTRK2 status may eventually become one additional research-grade data point to discuss with your clinician, but it does not yet replace established prescribing tools.

Severe Obesity and Hyperphagia

A subset of severe early-onset obesity is monogenic, meaning it traces to a single high-impact gene variant rather than the usual mix of diet, lifestyle, and many small genetic effects. NTRK2 is one of those genes. In a cohort of 44 affected individuals, loss-of-function NTRK2 variants produced a pattern of milder developmental delay paired with obesity and hyperphagia, the medical term for an intense, hard-to-control drive to eat.

Pediatric obesity clinics that sequence relevant genes occasionally identify NTRK2 variants as a cause of single-gene obesity, though this is much rarer than mutations in genes like MC4R. A separate analysis identified a rare NTRK2 variant called p.S249Y that increases TRKB signaling in lab experiments and may contribute to severe obesity in carriers. If extreme appetite or unexplained early obesity runs in your family, knowing whether NTRK2 is involved can change the conversation with a specialist about treatment options.

Symptom Burden, Stress, and Other Behavioral Traits

NTRK2 variation has been studied beyond mood and weight, though most findings come from single studies that need replication. In women undergoing breast cancer chemotherapy, genotype at NTRK2 rs1212171 was linked to both sleep disturbance and fatigue. An awake bruxism (daytime teeth grinding) study found that the G allele at NTRK2 rs1867283 was more common in people with the condition, fitting a broader role for NTRK2 in stress coping. Gambling disorder research also implicated NTRK2 haplotypes as part of the inherited vulnerability.

Cancer and Tumor Testing

NTRK2 also matters in oncology, but in a different way. Rare events called gene fusions can splice NTRK2 to another gene inside a tumor, creating a hyperactive version of the TRKB receptor that drives cancer growth. These NTRK2 fusions show up most often in pediatric and infant brain tumors, where they define a distinct subgroup, and they are also found at low rates across many adult solid tumors.

When an NTRK fusion is detected in a tumor, it becomes a powerful target. Drugs called TRK inhibitors (larotrectinib and entrectinib) produced objective responses in 75 percent of patients in an initial pooled analysis of 55 adults and children, and in 93 percent of pediatric patients in a separate phase 1 study of TRK fusion-positive solid tumors. A larger pooled analysis of 304 patients later reported an overall response rate closer to 65 percent. Across many tumor types, somatic mutations in the NTRK gene family have also been associated with better response to immune checkpoint inhibitors, though melanoma-specific evidence comes from a single study. The fusion testing done on tumor tissue is a separate process from inherited NTRK2 genotyping, but the two pieces of biology share the same receptor.

One-Time Result, Lifetime Use

Your NTRK2 genotype is fixed at conception and does not change with age, diet, stress, or any intervention. You do not retest this marker year after year the way you would track cholesterol or HbA1c (a measure of average blood sugar). One accurate result is the data you carry for life.

What changes over time is how you use the result. If you are considering or already on antidepressants or mood stabilizers, the NTRK2 result becomes a research-grade reference your prescriber may consult alongside established tools at medication decisions. If you carry a rare high-impact variant linked to single-gene obesity or developmental risk, the result drives more frequent monitoring of weight, growth (in children), and metabolic markers, plus targeted referrals. The value compounds across decades of decisions.

When Results Can Be Misleading

• Panel coverage limits: the assay only reads the specific NTRK2 variants it is designed to detect. A negative result does not rule out other rare variants in the gene that the panel does not cover, especially deep intronic or large structural changes.
• Ancestry-specific variants: several NTRK2 findings come from specific populations, such as Mexican-American depression cohorts or African-ancestry bipolar studies. The clinical meaning of a particular variant can vary by ancestry, so genetic counseling helps interpret a result in context.
• Variants of uncertain significance: sequencing may turn up an unexpected NTRK2 change that has not been seen often enough to classify as benign or harmful. The lab report will flag this, and the variant may be reclassified over time as more data accumulate.
• Direct-to-consumer vs clinical-grade testing: consumer genetic reports often only check a handful of common NTRK2 positions. A clinical-grade test reads a wider stretch of the gene and is much more likely to catch the rare high-impact variants that actually change management.

What to Do With an Out-of-Pattern Result

If your NTRK2 genotype identifies a variant linked to a high-impact condition, the next steps depend on which pattern is involved. For a variant tied to severe obesity or hyperphagia, the natural pathway is a referral to an endocrinologist or obesity medicine specialist familiar with single-gene obesity, plus more aggressive monitoring of weight, metabolic labs, and growth. For a variant tied to depression or antidepressant response, the result becomes part of the conversation with a psychiatrist, recognizing that NTRK2 is not yet part of guideline-endorsed pharmacogenomic prescribing. For any rare or high-impact NTRK2 variant, a session with a genetic counselor is appropriate, both to understand the result and to discuss whether siblings, parents, or children should consider testing.

For common variants linked to anxiety liability, antidepressant response, or symptom burden, the action is more subtle. Treat the result as one input among many: family history, personal history of mood or anxiety symptoms, and response to any previous treatments. Confirmatory sequencing by a different method may be warranted if the call comes from a SNP chip rather than full sequencing.

Where the Science Stands

NTRK2 genotyping is not a routine screening test in the way that a lipid panel is. The high-impact rare variants linked to obesity and developmental syndromes have strong evidence behind them. The common variants linked to anxiety, antidepressant response, and symptom burden are real but modest in effect, the evidence is mixed for pharmacogenomic use, and NTRK2 is not included in standard pharmacogenomic guidelines. Knowing your status now gives you a baseline to combine with the larger picture as the research matures.